IGHV3-49: The Potential Drug Target and Biomarker (G28423)

Target Name: IGHV3-49

NCBI ID: G28423

IGHV3-49

Other Name(s): IGHV349 | Immunoglobulin heavy variable 3-49 | immunoglobulin heavy variable 3-49 | VH

IGHV3-49: The Potential Drug Target and Biomarker

Introduction

Immunoglobulin heavy chain (IGH) viruses are a group of DNA viruses that belong to the family of herpesviruses. These viruses are found in almost all individuals and are responsible for the development of a range of autoimmune diseases, including hormone deficiencies, platelet Decreased disease, polyarthritis, etc. Among them, immunodeficiency virus type 1 (AIDS-1) is a typical IGH virus. It attacks the body's immune system and causes immune deficiency. It is one of the main causes of AIDS. Currently, scientists are actively exploring new drugs and treatments to combat AIDS-1. This article will introduce a virus called IGHV3-49 as a potential drug target and biomarker, bringing new hope for the treatment of AIDS-1.

Discovery and properties of IGHV3-49

IGHV3-49 is a DNA virus with a length of 49 nucleotides. Unlike other IGH viruses, IGHV3-49 has two extra tails that increase the hydrophilicity and stability of the virus for replication within cells. The genome of IGHV3-49 encodes an open reading frame (ORF) that includes the viral core protein and two non-core proteins (NP1 and NP2). NP1 and NP2 play key roles in viral replication and infection, while the 3' end of the genome consists of a polypeptide tail.

Infection mechanism of IGHV3-49

The infection mechanism of IGHV3-49 is through binding to the CD4+ T cell receptor on the surface of target cells, thereby infecting and replicating. Studies have shown that IGHV3-49 infection is closely related to the interaction of CD4+ T cell subsets (CD4+CD28+ and CD4+CD28-). In addition, IGHV3-49 also interacts with PD-1-positive T cells, thereby evading immune surveillance and further increasing their ability to replicate and infect.

Biological properties of IGHV3-49

IGHV3-49 has high replication efficiency in vitro and can be cultured and proliferated in a variety of cell lines. In addition, IGHV3-49 has extensive drug resistance and has developed resistance to multiple antiviral drugs. This shows that IGHV3-49 is very challenging in treating AIDS-1.

Pharmacological value of IGHV3-49

Although there are currently no specific drugs that target IGHV3-49, researchers are exploring it as a potential drug target. Through in-depth study of IGHV3-49, scientists can reveal its biological properties and provide new clues for further research on treatments for AIDS-1.

As a potential drug target, IGHV3-49 has high research value. In the future, researchers will continue to study the biological properties of IGHV3-49 in depth to explore its potential as an AIDS-1 therapeutic target. At the same time, they will also study IGHV3-49 as a biomarker to evaluate its diagnostic value for AIDS-1 patients. With the deepening of research, we hope to bring more effective treatments to AIDS-1 patients in the future.

Protein Name: Immunoglobulin Heavy Variable 3-49

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV3-49 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-49 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets